In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Wave Life Sciences (WVE – Research Report), with a price target of $13.00. The company’s shares opened today at $3.66.
Syed covers the Healthcare sector, focusing on stocks such as Cytokinetics, Atara Biotherapeutics, and Biogen. According to TipRanks, Syed has an average return of -16.3% and a 33.33% success rate on recommended stocks.
Wave Life Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $10.50, representing a 186.89% upside. In a report released on September 20, H.C. Wainwright also maintained a Buy rating on the stock with a $8.00 price target.
See today’s best-performing stocks on TipRanks >>
WVE market cap is currently $316.9M and has a P/E ratio of -1.84.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
Read More on WVE:
- Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor Event
- Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines Conference
- Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease
- Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022
- Why Is Wave Life Sciences Stock Surging Despite Q2 Miss?
